CME Presentations




  • John Strickler, MD

    John Strickler, MD

  • Tanios Bekaii-Saab, MD, FACP

    Tanios Bekaii-Saab, MD, FACP

    Tanios Bekaii-Saab, MD, FACP

    Section Chief, Gastrointestinal Oncology

    Tanios Bekaii-Saab, MD, FACP, is professor of medicine and pharmacy at The Ohio State University Comprehensive Cancer Center (OSUCCC), where he also is section chief, gastrointestinal oncology, and chair of the OSUCCC Gastrointestinal Disease Research Group. Dr Bekaii-Saab earned his medical degree at the American University of Beirut in Lebanon. He completed his internal medicine residency at the Indiana University Medical Center in Indianapolis, and hematology/oncology and clinical pharmacology fellowships at Tufts University-New England Medical Center in Boston. Dr Bekaii-Saab's research interests include experimental therapeutics/translational research focused on molecularly-targeted and immune-mediated therapies in gastrointestinal (GI) cancers, and more specifically, pancreatic and biliary cancers. He is the principal investigator on numerous clinical trials, including studies supported through research grants from the National Cancer Institute (NCI) and the National Comprehensive Cancer Network (NCCN). Additionally, Dr Bekaii-Saab has authored or co-authored articles in several publications that include the Journal of the National Cancer Institute, American Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, and Drugs.

CME Information

Global Logo PQH Logo
A New Path for HER2-positive Metastatic Colorectal Cancer
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC.


This activity is supported by an educational grant from Seagen Inc.


Wednesday, February 8 from 3:00-4:00pm ET.


Oncologists - medical, surgical, radiation; gastroenterologists, in addition to oncology nurses; NP/PA in oncology settings; oncology pharmacists


Novel investigational targeted therapies have shown encouraging results in patients with HER2+ metastatic colorectal cancer (mCRC). To ensure these therapies are used effectively, it is important to test for tumor HER2 status and recognize where HER2-directed treatment modalities fit into the current paradigm.

Join a panel of expert gastrointestinal oncologists to discuss selection of the most appropriate therapy based on tumor biomarker status, minimization of adverse events, and strategies to improve patient quality of life. Panelists will review practice-changing data on the efficacy and safety of new and emerging therapies, with a focus on HER2-directed therapies in the advanced setting and determining which treatments are appropriate for which patients.


After completing this activity, the participant should be better able to:
  • Discuss HER2 testing and its significance for selecting therapy in the management of patients with mCRC
  • Evaluate efficacy data from practice-changing clinical trials on new and emerging HER2-directed therapies for previously treated mCRC
  • Outline adverse events associated with HER2-directed therapies and approaches to mitigate these effects


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 60 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter Reported Financial Relationship
Tanios Bekaii-Saab, MD
Mayo Clinic
To be disclosed prior to presentation.
John Strickler, MD
Associate Professor
Associate Director of Clinical Research – GI Oncology
Co-Leader of the Molecular Tumor Board.
Duke University
To be disclosed prior to presentation.

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager Reported Financial Relationship
Rhys Williams, MSN, FNP-C, RN Nothing to disclose
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Lauren Sinclair Nothing to disclose
Tariqa Ackbarali Nothing to disclose
Caroline Laurendeau Nothing to disclose


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at